Analysis of MicroRNA -155-5p Expression in Patients with Primary Myelofibrosis.

Sarah I. Khaleel; Jaffar N.  AlAlsaidissa

doi:10.32007/jfacmedbaghdad.6642400

المؤلفون

Sarah I. Khaleel Department of Pathology and Forensic Medicine, College of Medicine University of Baghdad, Baghdad, Iraq. https://orcid.org/0009-0001-7975-4096
Jaffar N. AlAlsaidissa Department of Pathology and Forensic Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq. https://orcid.org/0000-0002-8065-6725

DOI:

https://doi.org/10.32007/jfacmedbaghdad.6642400

الكلمات المفتاحية:

اضطراب تكاثري نقوي، التليف النقوي الأولي، MicroRNA

الملخص

الخلفية

التنزيلات

تنزيل البيانات ليس متاحًا بعد.

المراجع

1. Bose P, Masarova L, Amin HM, Verstovsek S. Philadelphia chromosome-negative myeloproliferative neoplasms (Chapter 6). In: Kantarjian HM, Wolff RA, Rieber AG, eds. The MD Anderson Manual of Medical Oncology. 4th ed. McGraw-Hill, LLC: China; 2022. pp. 119-162. https://accessmedicine.mhmedical.com/content.aspx?bookid=3151&sectionid=264035510

2. Gangat N, Tefferi A. Myelofibrosis biology and contemporary management. Br J Haematol. 2020 Oct;191(2):152-170. https://doi.org/10.1111/bjh.16576.

3. Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021 Jan;96(1):145-162. https://doi.org/10.1002/ajh.26050.

4. Tremblay D, Mascarenhas J. Next Generation Therapeutics for the Treatment of Myelofibrosis. Cells. 2021 Apr 27;10(5):1034. https://doi.org/10.3390/cells10051034.

5. Curto-Garcia N, Harrison C, McLornan DP. Bone marrow niche dysregulation in myeloproliferative neoplasms. Haematologica. 2020 May;105(5):1189-1200. https://doi.org/10.3324/haematol.2019.243121.

6. Ng ZY, Fuller KA, Mazza-Parton A, Erber WN. Morphology of myeloproliferative neoplasms. Int J Lab Hematol. 2023 Jun;45 Suppl 2:59-70. https://doi.org/10.1111/ijlh.14086.

7. Chifotides HT, Bose P, Verstovsek S. Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol. 2022 Jan 19;15(1):7. https://doi.org/10.1186/s13045-021-01157-4.

8. Passamonti F, Harrison CN, Mesa RA, Kiladjian JJ, Vannucchi AM, Verstovsek S. Anemia in myelofibrosis: Current and emerging treatment options. Crit Rev Oncol Hematol. 2022 Dec;180:103862. https://doi.org/10.1016/j.critrevonc.2022.103862.

9. Fuentes-Mattei E, Bayraktar R, Manshouri T, Silva AM, Ivan C, Gulei D,et al. miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. JCI Insight. 2020 Jan 16;5(1):e121781 https://doi.org/10.1172/jci.insight.121781.

10. Sastow D, Tremblay D. Emerging Treatment Options for Myelofibrosis: Focus on Anemia. Ther Clin Risk Manag. 2023 Jun 28;19:535-547. https://doi.org/10.2147/TCRM.S386802.

11. Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023 May;98(5):801-821. https://doi.org/10.1002/ajh.26857.

12. Abbas DD, Al-Rubaie HA. Association of Microrna-153-3p Expression in Response to Treatment with Imatinib in Patients with Chronic Myeloid Leukemia. The Egyptian Journal of Hospital Medicine. 2023 Jan 1;90(1):1049-52. https://doi.org/10.21608/ejhm.2023.280208.

13. Mehjabin A, Kabir M, Micolucci L, Akhtar MM, Mollah AKMM, Islam MS. MicroRNA in Fibrotic Disorders: A Potential Target for Future Therapeutics. Front Biosci (Landmark Ed). 2023 Nov 29;28(11):317. https://doi.org/10.31083/j.fbl2811317.

14. Mohd Yacob A, Muhamad NA, Chang KM, Akmal Hisham H, Mat Yusoff Y, Ibrahim L. Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response. BMC Cancer. 2022 Mar 26;22(1):332. https://doi.org/10.1186/s12885-022-09396-5

15. Szelenberger R, Kacprzak M, Saluk-Bijak J, Zielinska M, Bijak M. Plasma MicroRNA as a novel diagnostic. Clin Chim Acta. 2019 Dec;499:98-107. https://doi.org/10.1016/j.cca.2019.09.005.

16. Elton TS, Selemon H, Elton SM, Parinandi NL. Regulation of the MIR155 host gene in physiological and pathological processes. Gene. 2013 Dec 10;532(1):1-12. https://doi.org/10.1016/j.gene.2012.12.009.

17. Garmezy B, Schaefer JK, Mercer J, Talpaz M. A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management. Blood Rev. 2021 Jan;45:100691. https://doi.org/10.1016/j.blre.2020.100691.

18. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM,et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-1228. https://doi.org/10.1182/blood.2022015850.

19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001 Dec;25(4):402-8. https://doi.org/10.1006/meth.2001.1262.

20. Tremblay D, Yacoub A, Hoffman R. Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications. Hematol Oncol Clin North Am. 2021 Apr;35(2):159-176. https://doi.org/10.1016/j.hoc.2020.12.001.

21. Hu J, Huang S, Liu X, Zhang Y, Wei S, Hu X. miR-155: an important role in inflammation response. Journal of immunology research. 2022 Apr 6;2022 https://doi.org/10.1155/2022/7437281.

22. Tang L, Peng Y, Li C, Jiang HW, Mei H, Hu Y. Prognostic and Clinicopathological Significance of MiR-155 in Hematologic Malignancies: A Systematic Review and Meta-analysis. J Cancer. 2019;10(3):654-64. https://doi.org/10.7150/jca.28537.

23. Tombak A, Ay OI, Erdal ME, Sungur MA, Ucar MA, Akdeniz A,et al. MicroRNA expression analysis in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Indian J Hematol Blood Transfus. 2015 Dec;31(4):416-25. https://doi.org/10.1007/s12288-014-0492-z.

24. Norfo R, Zini R, Pennucci V, Bianchi E, Salati S, Guglielmelli P, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. Blood. 2014 Sep 25;124(13):e21-32. https://doi.org/10.1182/blood-2013-12-544197

25. Alwan AF. Clinical features and therapeutic outcome of 30 patients diagnosed with primary myelofibrosis at the National Center of Hematology. J Fac Med Baghdad. 2015 Jan. 4;56(4):362-6.

https://doi.org/10.32007/jfacmedbagdad.564545

26. Stolyar MA, Gorbenko AS, Bakhtina VI, Martynova EV, Moskov VI, Mikhalev MA, et al. Investigation of miR-155 level in the blood of patients with chronic lymphocytic leukemia and Ph-negative myeloproliferative neoplasms. Klin Lab Diagn. 2020;65(4):258-264. Russian. https://doi.org/10.18821/0869-2084-2020-65-4-258-264.